A comprehensive view of new dosage / format. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
ViiV Healthcare, Janssen Pharmaceutical receive FDA approval for label update for Cabenuva cabotegravir, non-nucleoside reverse transcriptase inhibitor rilpivirine injectable to treat HIV-1; approved dose is once-monthly or once every two months
Published: March 30, 2022 by Fitch Solutions Sector Intelligence
CanSinoBIO's Convidecia approved in Malaysia as a heterologous booster for individuals aged 18 and older who have received two doses of inactivated COVID-19 vaccine
Published: March 22, 2022 by Canada Newswire
Ask us about our R&D/Patents market view